Journal of Personalized Medicine
Menin Inhibitors in Acute Myeloid Leukemia: From Molecular Rationale to Clinical Practice
By Caterina Alati, Matteo Molica, Martina Pitea and 6 others.
Abstract
Background
Acute Myeloid Leukemia (AML) harboring KMT2A rearrangements (KMT2Ar) or NPM1 mutations (mNPM1) constitutes a substantial and molecularly coherent subset of AML characterized by aberrant activation of homeobox (HOX) gene programs driven by the menin–MLL transcriptional complex. Disruption of this interaction through small-molecule menin inhibitors represents a compelling therapeutic strategy.
Methods
We conducted a narrative (non-systematic) review of the clinical literature on four menin inhibitors—revumenib, ziftomenib, bleximenib, and enzomenib—as monotherapy and in combination regimens, identified through PubMed/MEDLINE and conference abstract searches (ASH, EHA) without a pre-specified systematic search protocol, as detailed in the Introduction.